Champion of treatments for cystic fibrosis (CF), US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has been moving to diversify its product offerings, and today announced positive results from two Phase II proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery.
This is Vertex’ fourth attempt to develop a sodium channel Nav1.8 inhibitor, after VX-128, VX-150 and VX-961 failed to impress, but the latest attempt did to a certain extent, with the firm’s shares up 1.7% at $260.97 on Thursday.
Pain represents Vertex’ bid to go beyond it CF comfort zone, but Stifel analysts cautioned that the area might not fit into the company’s high-margin business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze